
Please try another search
Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockville, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Moon-jong Noh | 56 | 2001 | CEO, President & Director |
Javad Parvizi | - | - | Member of Clinical Advisory Board |
David Hunter | - | 2016 | Member of Scientific Advisory Board |
Ali Mobasheri | - | 2020 | Member of the Scientific Advisory Board |
Philip G. Conaghan | - | 2017 | Member of Scientific Advisory Board |
Terry L. Lierman | 77 | - | Member of Business Advisory Board |
Peter Shin | - | - | Member of Business Advisory Board |
Michael A. Mont | - | - | Member of Clinical Advisory Board |
Jeon Seungho | 50 | 2025 | Director |
Jung In Kim | 47 | 2021 | CFO & Director |
SunJoo Lee | 58 | 2023 | Independent Outside Director |
Seng-Ho Jeon | 55 | 2025 | CEO & Director |
Young J. Kim | 63 | 2021 | Statutory Auditor & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review